The peri-procedural use of dabigatran in patients undergoing left atrial ablation for atrial fibrillation

Cardiovascular Therapeutics

Volumn 32, Issue 5, 2014, Pages 198-201

  Somani, Riyaz ^a   Mohajer, Kiarash ^a   Haley, Charlotte ^a   Simpson, Christopher S ^a   Abdollah, Hoshiar ^a   Baranchuk, Adrian ^a   Redfearn, Damian P ^a   Michael, Kevin ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Atrial fibrillation; Dabigatran; Pulmonary veinisolation; Warfarin

Indexed keywords

ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN;

AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CATHETER ABLATION; ECHOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84908393214     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12082     Document Type: Article

References (11)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
3. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. Europace 2007;9:335-379.
4. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007;116:2531-2534.
5. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013;10:483-489.
6. Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013;24:861-865.
7. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550-2556.
8. Garnock-Jones KP. Dabigatran etexilate. A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011;11:57-72.
9. Sartori MT, Imbergamo S, Zanon E, et al. Effect of recombinant activated factor VII in critical bleeding: Clinical experience of a single center. Clin Appl Thromb Hemost 2009;119:121-127.
10. van Ryn J, Ruehl D, Priepke H, et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate (Abstract 0370). Haematologica 2008;93(Suppl. 1):148.
11. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 2012;59:1168-1174.